
EquitySector - HealthcareVery High Risk
Direct
NAV (18-Nov-25)
Returns (Since Inception)
Fund Size
₹1,325 Cr
Expense Ratio
0.62%
ISIN
INF277K019A3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+6.67%
+6.09% (Cat Avg.)
3 Years
+24.00%
+22.96% (Cat Avg.)
5 Years
+19.47%
+18.05% (Cat Avg.)
Since Inception
+13.78%
— (Cat Avg.)
| Equity | ₹1,305.07 Cr | 98.50% |
| Others | ₹19.83 Cr | 1.50% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹127.09 Cr | 9.59% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹68 Cr | 5.13% |
| HealthCare Global Enterprises Ltd | Equity | ₹65.76 Cr | 4.96% |
| Lupin Ltd | Equity | ₹64.97 Cr | 4.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹62.44 Cr | 4.71% |
| Torrent Pharmaceuticals Ltd | Equity | ₹59.95 Cr | 4.52% |
| Alkem Laboratories Ltd | Equity | ₹58.61 Cr | 4.42% |
| Abbott India Ltd | Equity | ₹53.31 Cr | 4.02% |
| Cipla Ltd | Equity | ₹51.96 Cr | 3.92% |
| Ipca Laboratories Ltd | Equity | ₹47.12 Cr | 3.56% |
| Ajanta Pharma Ltd | Equity | ₹44.43 Cr | 3.35% |
| Rainbow Childrens Medicare Ltd | Equity | ₹43.7 Cr | 3.30% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹43.6 Cr | 3.29% |
| Divi's Laboratories Ltd | Equity | ₹43.19 Cr | 3.26% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹42.68 Cr | 3.22% |
| Metropolis Healthcare Ltd | Equity | ₹42.1 Cr | 3.18% |
| FDC Ltd | Equity | ₹38.77 Cr | 2.93% |
| Dr. Lal PathLabs Ltd | Equity | ₹38.29 Cr | 2.89% |
| Mankind Pharma Ltd | Equity | ₹34.81 Cr | 2.63% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹30.87 Cr | 2.33% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹28.81 Cr | 2.17% |
| PI Industries Ltd | Equity | ₹28.78 Cr | 2.17% |
| Sai Life Sciences Ltd | Equity | ₹27.63 Cr | 2.09% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹26.57 Cr | 2.01% |
| Syngene International Ltd | Equity | ₹23.37 Cr | 1.76% |
| Dr Reddy's Laboratories Ltd | Equity | ₹21.66 Cr | 1.63% |
| Cohance Lifesciences Ltd | Equity | ₹20.02 Cr | 1.51% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹19.85 Cr | 1.50% |
| Wockhardt Ltd | Equity | ₹18.74 Cr | 1.41% |
| A) Repo | Cash - Repurchase Agreement | ₹12.98 Cr | 0.98% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹11.86 Cr | 0.89% |
| Hikal Ltd | Equity | ₹9.39 Cr | 0.71% |
| Cash / Net Current Asset | Cash | ₹6.85 Cr | 0.52% |
| Pfizer Ltd | Equity | ₹5.53 Cr | 0.42% |
| Jubilant Pharmova Ltd | Equity | ₹0.75 Cr | 0.06% |
| Laxmi Dental Ltd | Equity | ₹0.45 Cr | 0.03% |
Large Cap Stocks
40.31%
Mid Cap Stocks
19.70%
Small Cap Stocks
38.49%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,276.29 Cr | 96.33% |
| Basic Materials | ₹28.78 Cr | 2.17% |
Standard Deviation
This fund
16.07%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
0.99
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since September 2024
ISIN INF277K019A3 | Expense Ratio 0.62% | Exit Load No Charges | Fund Size ₹1,325 Cr | Age 9 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,10,488 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Direct
NAV (18-Nov-25)
Returns (Since Inception)
Fund Size
₹1,325 Cr
Expense Ratio
0.62%
ISIN
INF277K019A3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+6.67%
+6.09% (Cat Avg.)
3 Years
+24.00%
+22.96% (Cat Avg.)
5 Years
+19.47%
+18.05% (Cat Avg.)
Since Inception
+13.78%
— (Cat Avg.)
| Equity | ₹1,305.07 Cr | 98.50% |
| Others | ₹19.83 Cr | 1.50% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹127.09 Cr | 9.59% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹68 Cr | 5.13% |
| HealthCare Global Enterprises Ltd | Equity | ₹65.76 Cr | 4.96% |
| Lupin Ltd | Equity | ₹64.97 Cr | 4.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹62.44 Cr | 4.71% |
| Torrent Pharmaceuticals Ltd | Equity | ₹59.95 Cr | 4.52% |
| Alkem Laboratories Ltd | Equity | ₹58.61 Cr | 4.42% |
| Abbott India Ltd | Equity | ₹53.31 Cr | 4.02% |
| Cipla Ltd | Equity | ₹51.96 Cr | 3.92% |
| Ipca Laboratories Ltd | Equity | ₹47.12 Cr | 3.56% |
| Ajanta Pharma Ltd | Equity | ₹44.43 Cr | 3.35% |
| Rainbow Childrens Medicare Ltd | Equity | ₹43.7 Cr | 3.30% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹43.6 Cr | 3.29% |
| Divi's Laboratories Ltd | Equity | ₹43.19 Cr | 3.26% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹42.68 Cr | 3.22% |
| Metropolis Healthcare Ltd | Equity | ₹42.1 Cr | 3.18% |
| FDC Ltd | Equity | ₹38.77 Cr | 2.93% |
| Dr. Lal PathLabs Ltd | Equity | ₹38.29 Cr | 2.89% |
| Mankind Pharma Ltd | Equity | ₹34.81 Cr | 2.63% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹30.87 Cr | 2.33% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹28.81 Cr | 2.17% |
| PI Industries Ltd | Equity | ₹28.78 Cr | 2.17% |
| Sai Life Sciences Ltd | Equity | ₹27.63 Cr | 2.09% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹26.57 Cr | 2.01% |
| Syngene International Ltd | Equity | ₹23.37 Cr | 1.76% |
| Dr Reddy's Laboratories Ltd | Equity | ₹21.66 Cr | 1.63% |
| Cohance Lifesciences Ltd | Equity | ₹20.02 Cr | 1.51% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹19.85 Cr | 1.50% |
| Wockhardt Ltd | Equity | ₹18.74 Cr | 1.41% |
| A) Repo | Cash - Repurchase Agreement | ₹12.98 Cr | 0.98% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹11.86 Cr | 0.89% |
| Hikal Ltd | Equity | ₹9.39 Cr | 0.71% |
| Cash / Net Current Asset | Cash | ₹6.85 Cr | 0.52% |
| Pfizer Ltd | Equity | ₹5.53 Cr | 0.42% |
| Jubilant Pharmova Ltd | Equity | ₹0.75 Cr | 0.06% |
| Laxmi Dental Ltd | Equity | ₹0.45 Cr | 0.03% |
Large Cap Stocks
40.31%
Mid Cap Stocks
19.70%
Small Cap Stocks
38.49%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,276.29 Cr | 96.33% |
| Basic Materials | ₹28.78 Cr | 2.17% |
Standard Deviation
This fund
16.07%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
0.99
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since September 2024
ISIN INF277K019A3 | Expense Ratio 0.62% | Exit Load No Charges | Fund Size ₹1,325 Cr | Age 9 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,10,488 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments